Biopharma Tie-Ups and Quebecois Weed Woes
In this week's episode of Industry Focus: Healthcare, host Shannon Jones and Motley Fool analyst Todd Campbell dig into two recent industry headlines -- first, the merger between pharma giant Pfizer (NYSE: PFE) and Mylan (NASDAQ: MYL), a generics manufacturer best known for drawing widespread ire over their EpiPen pricing. Find out what this deal does for both companies, what will happen to existing shareholders, what Mylan shareholders should think about before they cash out, and more. On the back half of the show, they look into some recent short interest for Canadian marijuana producer HEXO (NYSE: HEXO). They talk about what legal problems HEXO is running into, why the company's home base in Quebec could pose some serious trouble for them in the next few years, what investors should always remember about short reports, and much more.
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. A full transcript follows the video.
Source Fool.com
